semaglutide launch title Today we launch, Obeda®, India's first DCGI-approved generic injection for Type 2 Diabetes. This product reinforces our purpose of good health cant wait, to bring high quality and affordable treatment Novo preparing for early launch

The thymosin beta-4 eye-drop trials are real and rigorous, but they concern a topical ophthalmic product for corneal disease

PlexusDx Precision Peptide Genetic Test analyzes variants in GIPR and FTO, and MC4R genes that influence appetite regulation and metabolic response

Skipping a week then jumping to a higher dose shortcuts that adaptation and increases side-effect risk

Many researchers adjust their injection timing specifically for dose escalation weeks

During the full time period (2018 2024), 69.4% of GLP-1 RA prescriptions had a dispense within 60 days of their prescription (e.g., were initiated within 60 days)